LRIG1 has been reported to be a tumor suppressor in gastrointestinal tract and epidermis. However, little is known about the expression, regulation and biological functions of LRIG1 in prostate cancer (PCa). We find that LRIG1 isoverexpressed in PCa, but its expression correlates with better patient survival. Functional studies reveal strong tumor-suppressive functions of LRIG1 in […]
{{header-clinical-trials-navigation}} Patient-reported Outcomes in Bladder Cancer; a Multicentre Randomized Controlled Trial: The iBLAD Study Condition: Bladder Cancer, Urothelial Carcinoma Intervention: Device: Electronic patient-reported outcomes Purpose: Electronic reporting of patient-reported outcomes with alert algorithm will be tested in a randomized trial in bladder cancer patients undergoing chemo- or immunotherapy. The clinical endpoints will be: – Quality […]
{{header-clinical-trials-navigation}} Prospective Study of Adjuvant Radiotherapy in High Risk Bladder Cancer. Condition: Bladder Cancer Intervention: Radiation: Radiotherapy +/- CT Purpose: This prospective interventional study aims at evaluating the safety and efficacy of an adjuvant radiation treatment in cases of muscle-invasive bladder cancer, submitted to radical cystectomy and presenting clinic-pathological characteristics of high risk of recurrence. […]
{{header-clinical-trials-navigation}} Targeting a Genomic Biomarker for PET Imaging and Staging of Urothelial Cancer: A Preliminary Evaluation Condition: Bladder Urothelial Carcinoma, Urothelial Carcinoma Intervention: Drug: Copper Cu 64 TP3805 Procedure: Positron Emission Tomography Procedure: Computed Tomography Purpose: This pilot clinical trial studies how well copper Cu-64 TP3805 positron emission tomography (PET)/computed tomography (CT) works in imaging […]
{{header-clinical-trials-navigation}} A Pilot Study of Neoadjuvant sEphB4-HSA in Patients With Genitourinary Cancers Condition: Infiltrating Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma, Stage I Prostate Cancer, Stage I Renal Cell Cancer, Stage II Bladder Urothelial Carcinoma, Stage II Renal Cell Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage III Renal Cell […]
{{header-clinical-trials-navigation}} ODM-201 Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Subsequent Treatment With a Taxane: A Multicenter Randomized Double-blind Placebo-controlled Phase II Trial. Condition: Prostate Cancer Metastatic, Prostate Cancer Intervention: Drug: ODM-201 Other: Placebo Purpose: The main objective of the trial is […]
Simple orchiectomy for gender affirmation is a low-risk, minimally invasive, generalizable procedure that eliminates circulating endogenous testosterone, allowing reduced hormonal supplementation. This article describes a technique that serves as a step in definitive phenotypic transition while maximally preserving healthy tissue for future sex reassignment surgery.
Testicular cancer is the most common cancer among young men of European ancestry, with about one-third of all cases occurring in Europe. With the historically increasing trends in some high-incidence populations reported to have stabilised in recent years, we aimed to assess recent trends and predict the future testicular cancer incidence burden across Europe.
This study aimed to look into possible correlations between male age and different sperm parameters derived from semen analysis and sperm deoxyribonucleic acid (DNA) fragmentation. This retrospective descriptive study included 2681 male patients who underwent semen analysis at Clínica Las Condes (CLC), Santiago, Chile, between January 2014 and May 2017; correlations between age and sperm […]
The objective of this study is to assess the correlation between the urinary incontinence results of the ICIQ-SF, and those obtained in the 1-hour and 24-hour pad tests, in a sample of men that underwent prostatectomy.
